Targeted PET/MRI Imaging Super Probes: A Critical Review of Opportunities and Challenges
Anna Kastelik-Hryniewiecka,Pawel Jewula,Karolina Bakalorz,Gabriela Kramer-Marek,Nikodem Kuźnik
DOI: https://doi.org/10.2147/IJN.S336299
IF: 7.033
2022-01-01
International Journal of Nanomedicine
Abstract:Anna Kastelik-Hryniewiecka, 1, 2 Pawel Jewula, 3 Karolina Bakalorz, 1 Gabriela Kramer-Marek, 2, 4 Nikodem Ku&zacutenik 1 1 Silesian University of Technology, Faculty of Chemistry, Gliwice, Poland; 2 Radiopharmacy and Preclinical PET Imaging Unit, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland; 3 Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic; 4 Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK Correspondence: Nikodem Ku&zacutenik; Gabriela Kramer-Marek Tel +48 694 22 00 77; +44 208 722 4412 Fax +48 32 237 13 08; +44 207 370 5261 Email ; Recently, the demand for hybrid PET/MRI imaging techniques has increased significantly, which has sparked the investigation into new ways to simultaneously track multiple molecular targets and improve the localization and expression of biochemical markers. Multimodal imaging probes have recently emerged as powerful tools for improving the detection sensitivity and accuracy—both important factors in disease diagnosis and treatment; however, only a limited number of bimodal probes have been investigated in preclinical models. Herein, we briefly describe the strengths and limitations of PET and MRI modalities and highlight the need for the development of multimodal molecularly-targeted agents. We have tried to thoroughly summarize data on bimodal probes available on PubMed. Emphasis was placed on their design, safety profiles, pharmacokinetics, and clearance properties. The challenges in PET/MR probe development using a number of illustrative examples are also discussed, along with future research directions for these novel conjugates. Keywords: medical imaging, bioresponsive probes, targeting, contrast agents, relaxivity, clearance Efforts to improve the earlier diagnosis of cancer are multifaceted. Standard laboratory tests are beneficial due to their accessibility, relatively low costs, and specificity, but their routine use requires clear guidelines. 1 With the shift to non-invasive disease diagnosis and novel treatment regimens, molecular imaging has gathered remarkable momentum in practical applications over the past few decades and has played a profound role in monitoring disease progression and facilitating drug research. Imaging modalities allow for the non-invasive, real-time visualization and quantification of physiological and pathological processes at the cellular and molecular levels, allowing for the better management of cancer treatment. Currently, molecular imaging uses mainstream technologies such as X-ray computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT), as well as optical and ultrasound (US) imaging. These techniques require highly-sensitive instruments and specific imaging probes that link the imaging signal with a molecular event. Each of these modalities has pros and cons. For example, CT is widely available, has a fast acquisition time and high spatial resolution, but due to its poor sensitivity (10 −2 – 10 −3 mol/L), it is sometimes combined with SPECT or PET to capture biochemical and physiological processes. 2 Moreover, CT is associated with high radiation exposure and provides relatively low-contrast images of soft tissues. MRI does not use ionizing radiation, 3 has a high spatial resolution (~100 μm), 4 and delivers information about soft tissues, but it also has a low sensitivity. In contrast, PET has an extremely high sensitivity (10 −11 – 10 −12 mol/L), limitless depth of penetration, and quantitative capabilities, but it lacks anatomical parameters to identify molecular events. 5 Tremendous improvements have recently been made in the development of imaging modalities (eg, PET/MRI systems) and image reconstruction algorithms, and also in the design of novel imaging agents. Among these are probes that can directly recognize and bind to the targets of interest, as well as probes that are conjugated in a multivalent fashion to the surface of nanoparticles. Some probes may leverage natural processes for uptake or retention, and some be activated by disease-related processes. Our experience in the design and characterization of MRI and PET contrast agents has prompted us to critically review some of the benefits and possible pitfalls of the recently reported bimodal probes. Herein, we discuss how we can use physicochemical properties to predict major in vivo effects such as the clearance route and undesired deposition in various systems and how to assess the dose required to achieve signal enhancement in the region of -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology